HOME > Investors >
Press Releases
2018-04-11
ViroMed Announces PG201’s Potential Effect on Multiple Sclerosis in International Journal
2018-03-14
2018.03(IR letter) BusinessUpdates
2018-01-25
ViroMed’s gene therapy candidate valued at over W10tr
2017-11-17
ViroMed Builds Team of Experts to Complete New Global Drug Development
2017-11-06
VM BioPharma Announces Generic Name “donaperminogene seltoplasmid” for Investigational Novel Gene Therapy, VM202
1
2
3
4
5
6
7
8
9
10
